{"id":"W2017218408","doi":"10.1097/cad.0b013e328011fd99","title":"An open-label, multicenter phase II trial of capecitabine in patients with cisplatin-refractory or relapsed germ cell tumors","year":2007,"lang":"en","type":"article","venue":"Anti-Cancer Drugs","topic":"Testicular diseases and treatments","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Capecitabine; Medicine; Neutropenia; Tolerability; Internal medicine; Chemotherapy; Gastroenterology; Cisplatin; Transplantation; Refractory (planetary science); Germ cell tumors; Surgery; Progressive disease; Multicenter trial; Oncology; Adverse effect; Cancer; Randomized controlled trial; Multicenter study","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001690929,0.0002473707,0.0005279326,0.0001402445,0.00007139747,0.0000169517,0.0001750899,0.00007064408,0.0003210391],"category_scores_gemma":[0.00003920476,0.0001677012,0.00004208136,0.0002789118,0.00007484571,0.0002588621,0.00006658258,0.0001479675,0.000008462564],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001293441,"about_ca_system_score_gemma":0.0002467171,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006588628,"about_ca_topic_score_gemma":0.0001155487,"domain_scores_codex":[0.9982668,0.00004010801,0.0005105438,0.0004021761,0.000416126,0.0003642218],"domain_scores_gemma":[0.99875,0.00006448511,0.0003299575,0.000447896,0.0001527744,0.0002548855],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.339884,0.1045051,0.498621,0.0002063955,0.0002785153,0.0003361254,0.001070492,0.000006822506,0.004620655,0.000007302133,0.0002514253,0.05021218],"study_design_scores_gemma":[0.6320537,0.02256824,0.3383034,0.0003848978,0.0003974662,9.008917e-7,0.0001652764,0.00009758169,0.005238421,0.000001925326,0.0005066061,0.000281623],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9971998,0.0001430749,0.00001049245,0.00003488701,0.0001741904,0.001836963,0.0001200207,0.00002562239,0.0004549171],"genre_scores_gemma":[0.9982601,0.00003436452,0.0006355084,0.0001975329,0.00008532514,0.00004867113,0.0002107543,0.00004864435,0.0004790694],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2921697,"threshold_uncertainty_score":0.6838655,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01958008612328598,"score_gpt":0.3350720642321228,"score_spread":0.3154919781088368,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}